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Thyroid related autoantibodies have been related to the
development of encephalopathy, known as Hashimoto’s
encephalopathy. However, their relation with the encepha-
lopathy occurring in patients with Graves’ disease has not
been well established. The case is reported of a 51 year
old woman presenting with subacute progressive dementia
with evidence of hyperthyroidism. She had Graves’
disease associated with high titres of thyroid related
autoantibodies. Her encephalopathy was not improved by
antithyroid drugs, but promptly responded to corticosteroid
treatment, and stabilised with a gradual reduction of
thyroid related autoantibody titres. Brain positron emission
tomography initially showed a diffuse and multifocal
cerebral hypometabolism with subsequent normalisation
on her clinical recovery, which was consistent with the
acute and reversible cerebral inflammation probably
mediated by autoimmune mechanisms.
Myxedema and thyrotoxicosis are known causes oftreatable dementia. Additionally, thyroid relatedautoantibodies (TRAb) can precipitate an encepha-
lopathy even in the euthyroid state, which was named Hashi-
moto’s encephalopathy (HE) by Brain et al in 1966.1
We report on a patient presenting with a subacutely
progressive dementia,multifocal myoclonus, and raised TRAb.
The patient was found to fit the diagnostic criteria of both
Graves’ disease (GD) and HE.2 We also report the findings of
the 18 F-fluorodeoxyglucose positron emission tomography
(FDG-PET) conducted during the exacerbation and the recov-
ery phases of the thyrotoxic autoimmune encephalopathy.
CASE REPORT
A 51 year old right handed woman was brought to the hospi-
tal because of progressive cognitive deterioration and behav-
ioural changes, with associated involuntary movements that
had occurred during the past two weeks. She was a high
school graduate and ran a dress repair shop. She had been
healthy until six months ago,when she reported frequent heat
intolerance with a significant weight loss, from 60 kg to 45 kg
over the previous six months. However, she had been reliable
and efficient at her work until two weeks previously, when she
began to ask how to operate the dryer that she had used for
years. She seemed to be in a mildly depressed mood, and
somewhat withdrawn, with decreased verbal fluency. One
week before her admission she had difficulty in finding words,
spent hours searching for familiar objects, and could not recall
her working schedules. These symptoms further progressed
and developed into mental confusion, impaired language and
communication skills, and diffuse tremulousness.
On admission, her blood pressure was 130/80 mm Hg, with
a pulse rate of 110 per minute and a body temperature of
36.8°C. Physical examination revealed a restless thin, middle
aged woman in no acute distress. Exophthalmos was present
bilaterally, but the thyroid gland was not enlarged. On neuro-
logical examination, she was alert, but disoriented to time and
place. She could follow simple commands, but was apprehen-
sive and restless with a pronounced decrease in attention span
and memory. She failed to give a reliable medical history and
her Korean-Mini Mental State Examination (K-MMSE) score
was only 3 of 30 (table 1), with one point for her person orien-
tation and two points for memory registration. She had aster-
ixis, postural tremors, and multifocal myoclonus in all four
extremities. Neuropsychological tests revealed severe impair-
ment in all aspects of cognition,with particular impairment in
concentration, anomia, amnesia, apraxia, visuospatial and
frontal executive dysfunctions. Detailed results of neuro-
psychological assessment (table 2) can be found on the jour-
nal web site (www.jnnp.com).
The thyroid function tests at that time showed hyperthy-
roidism state. The levels of antimicrosomal antibodies,
antithyroglobulin antibodies, and thyrotrophin binding inhib-
iting immunoglobulin were considerably increased (table 1).
The cerebrospinal fluid analysis showed a mildly increased
protein level (61 mg/dl), but with normal cell counts and glu-
cose level. A thyroid scan disclosed a diffuse goitre and
increased thyroid activity, consistent with GD. The EEG dem-
onstrated a diffuse background slowing with excessive diffuse
slow theta and delta waves. MRI of the brain revealed no
abnormality. She was initially treated with antithyroid
therapy for three days. Her heart rate normalised, but her cog-
nitive dysfunction showed no improvement, with further
deterioration in behaviour and involuntary movements. From
the fourth day of hospitalisation, she was intravenously given
20 mg per day of dexamethasone for five days, with significant
cognitive and behavioural improvements becoming noticeable
on day 3 of corticosteroid treatment. She has shown a good
clinical recovery and her K-MMSE score was significantly
improved to 22 points after the five day course of high dose
corticosteroid treatment. However, after the reduction in dex-
amethasone to 15 mg per day, she fell into a confused state
again. Her thyroid function at that time was in an euthyroid
state. The relapse of her mental deterioration was considered
to be related to the rapid reduction of dexamethasone, and she
was treated with high doses of intravenous corticosteroid
(methylprednisolone 1 g/day for five days), which was
followed by prednisolone (60 mg/day), and showed an excel-
lent clinical recovery over the next three days. On the 18th day,
she was discharged from the hospital completely recovered.
Two weeks after the discharge she remained neurologically
stable, which was confirmed by a K-MMSE score of 28 of 30.
The thyroid function test showed an euthyroid state and the
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titres of TRAb were significantly declined, but still raised
(table 1). Her improved condition has remained stable despite
a gradual reduction of prednisolone to 30 mg/day over the
subsequent three months after which she did not attend
follow up appointments.
PET findings
PET was performed using a GE Advanced PET scanner (GE,
Milwaukee, USA), with the patient’s eyes closed, but with the
patient exposure to the surrounding noise. She fasted from
midnight, 18F-FDG 5mCi was injected intravenously, and the
images obtained 40 minutes later, in three dimensional mode
for 15 minutes. The OSEM (Ordered Subset Expectation Max-
imisation)methodwas used to reconstruct the images,with an
image slice thickness of 3.3 mm. The imaging analysis was
conducted by two nuclear medicine specialists. The PET scan
performed on the third day of hospitalisation showed diffusely,
non-uniformly decreased FDG uptake throughout the cerebral
cortices, which affected the right parietal, right temporal and
left inferior frontal areas more severely. The follow up PET, at
two weeks after discharge, demonstrated a dramatic resolution
of the previously noted areas of hypometabolism (fig 1).
COMMENT
The patient had a subacute progressive encephalopathy, char-
acterised by diffuse cognitive impairment, restlessness, multi-
focal myoclonus, and evidence of thyrotoxicosis. Laboratory
tests revealed that she had GD, associated with raised TRAb.
The PET scan also revealed a diffuse and multifocal cerebral
glucose hypometabolism, which may have been responsible
for her global cognitive impairment. GD may cause an
encephalopathy by two independent mechanisms; as the
direct effect of the increased thyroid hormone or from the
TRAb related autoimmune mechanism. If the encephalopathy
was precipitated by the direct toxic effects of increased thyroid
hormones, it should be reversed by antithyroid treatment
alone, but this was not the case in our patient. In fact, she
deteriorated further during the phase of only antithyroid
treatment despite the normalisation of thyroid hormone
levels, but rapidly responded to the dexamethasone tretment.
Additionally, her symptoms relapsed shortly after reducing
the dose of dexamethasone, but responded again to a high
dose intravenous corticosteroid treatment, with a complete
recovery under the maintenance corticosteroid treatment. Her
clinical course strongly indicated that autoimmune mecha-
nisms have been responsible for her encephalopathy.
The encephalopathy associated with raised TRAb has been
termed HE because these thyroid diseases are mostly
Hashimoto’s thyroiditis. Moreover, most were presented in
either an euthyroid or a hypothyroid state.2 However; she was
diagnosed with GD and was in a state of hyperthyroidism at
the time of admission. There have been only two cases of HE,
associated with thyrotoxicosis, previously reported, with both
cases showing a dramatic response to corticosteroid
treatment.3 4 The diagnosed thyroid disease was: GD in one,3
but was uncertain in the other.4 Considering that GD,
associated with raised TRAb, can also precipitate HE, the term
proposed by Canton et al,3 encephalopathy associated to auto-
immune thyroid disease, seems more appropriate than Hashi-
moto’s encephalopathy.
The central nervous system symptoms of thyrotoxicosis are
mainly allusion or psychosis. However, some thyrotoxic
patients have been observed with mental confusion, seizure,
manic or depressive attack, and delusion,5 and they have often
responded to plasmapheresis6 or corticosteroid treatment.7
Although it has been reported that the incidence of raised
TRAb in those patients was low,8 TRAb have not been
evaluated in most patients, which makes it difficult to exclude
the possibility of autoimmune mechanisms as the universal
pathogenesis of thyrotoxic encephalopathy.
Various neuroimaging features have been reported in HE.9
MRI may show either normal, diffuse cortical atrophy, or
increased T2 signals in the subcortical or the mesiotemporal
regions, representing as diffuse oedema or inflammation. Sin-
gle photon emission computed tomography (SPECT) may
show multiple areas of hypoperfusion, and Forchetti et al sug-
gested autoimmune cerebral vasculitis as the aetiology of
hypoperfusion on SPECT.10 However, most patients with HE
have a normal erythrocyte sedimentation rate and angio-
graphic features,11 with a necropsy study revealing very pecu-
liar vascultitis involving only venules of the brain stem.12 Con-
sequently, it is uncertain whether the perfusion defect on
SPECT is attributable to vasculitis itself, or is a secondary
Table 1 Summary of patient’s laboratory finding and results of K-MMSE
Date HD 1 HD 5 HD 7 HD 9 HD 11 HD 17
Two weeks after
discharge
T3 (80–120 ng/dl) 657.21 63.98 87.57 105.74 168.94
fT4 (0.73–1.95 ng/dl) 8.11 1.9 1.04 1.35 1.41
TSH (0.35–3.5 uIU/ml) 0.26 0.15 0.13 0.02 0.08
AMA (50 IU/ml<NL) 3000< 4200 3000 1923.5 1650.1
TGB (50 IU/ml<NL) 125.09 105.2 88.91 102.74 40.84
TBII (12%<NL) 59.59 54.69 46.95 53.47 32.26
K–MMSE 3/30 8/30 22/30 28/30
AMA, antimicrosomal antibodies; fT4, free T4; HD, hospital day; K–MMSE, Korean version of Mini-Mental State Examination; NL, normal; TBII,
thyrotrophin binding inhibiting immunoglobulin; TGB, antithyroglobulin antibodies.
Figure 1 Brain PET using 18 F-fluorodeoxyglucose obtained 40
minutes after the injection. (Top) Selected transaxial PET images of
the brain during the height of the patient’s deterioration showed
diffusely decreased, non-uniform FDG uptake in the brain, most
severely affecting the right parietal, the right temporal, and the left
inferior frontal areas. The FDG uptake in the basal ganglia and the
thalamus were comparatively well preserved. (Below) Transaxial PET
images of the brain after the patient’s clinical improvement
demonstrated symmetric distribution of FDG suggesting a significant
improvement of the cerebral glucose metabolism compared with the
previous study.
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feature related to the autoantibody mediated cerebral inflam-
mation and oedema. Our patient had a normal MRI, but her
initial brain PET revealed a diffuse and multifocal cerebral
hypometabolism, which was consistent with her globally
affected severe cognitive impairment. The cerebral hypome-
tabolism was reversible and normalised in her follow up brain
PET as the improvement of central nervous system symptoms
and the decreased titres of TRAb. The underlying pathogenesis
of PET abnormalities is still unclear, but the autoimmune
mediated inflammation in multifocal brain structures is
certainly the most probable cause. The prompt clinical
response to the corticosteroid treatment, and the acute relapse
upon the reduction of the corticosteroid dose during her early
stay in hospital, when the titres for the TRAb were still
persistently increased, strongly supports that the encepha-
lopathy was precipitated by the autoimmune mediated
inflammatory reactions, rather than the direct effect of the
TRAb against neuronal function. We suggest that any attempt
to reduce the dose of corticosteroid should be delayed until a
significant lowering of the TRAb titres has been achieved.
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